Silodosin KMD-3213, also known as Rapaflo, is a medication used to treat the symptoms of benign prostatic hyperplasia (BPH), a condition characterized by enlargement of the prostate gland. It was developed by Kissei Pharmaceutical Company and approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of BPH.
Chemical name:
The chemical name of Silodosin KMD-3213 is 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide.
Molecular formula:
The molecular formula of Silodosin KMD-3213 is C25H32F3N3O4.
Formula weight:
The formula weight of Silodosin KMD-3213 is 495.54 g/mol.
CAS No:
The CAS number of Silodosin KMD-3213 is 160970-54-7.
Top ten keywords from Google and synonyms:
Synonyms: KMD-3213, 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide
Health benefits of Silodosin KMD-3213:
Silodosin KMD-3213 has been primarily used for the treatment of benign prostatic hyperplasia (BPH), a common condition that affects many men as they age. By blocking the activity of alpha-1 adrenergic receptors in the prostate gland, Silodosin KMD-3213 can help to relieve the symptoms of BPH, including urinary frequency, urgency, and difficulty urinating.
Potential effects:
Silodosin KMD-3213 works by selectively blocking the activity of alpha-1 adrenergic receptors in the prostate gland, which can help to relax the smooth muscle tissue and reduce the pressure on the urethra. By improving urine flow and reducing the symptoms of BPH, Silodosin KMD-3213 can improve the quality of life for affected individuals.
Product Mechanism:
Silodosin KMD-3213 is a selective alpha-1 adrenergic receptor antagonist that blocks the activity of alpha-1 adrenergic receptors in the prostate gland. By inhibiting the activity of these receptors, Silodosin KMD-3213 can help to relax the smooth muscle tissue in the prostate gland and improve urine flow. This mechanism of action is different from other medications used to treat BPH, such as 5-alpha-reductase inhibitors, which work by reducing the size of the prostate gland.
Safety:
Like any medication, Silodosin KMD-3213 may have some potential side effects. However, most reported side effects of Silodosin KMD-3213 are mild to moderate in severity and manageable. Common side effects include dizziness, headache, nausea, and fatigue. In rare cases, severe adverse reactions such as low blood pressure and allergic reactions may occur. Therefore, it is important to discuss the risks and benefits of Silodosin KMD-3213 with your doctor before taking it.
Dosing Information:
The recommended dosage of Silodosin KMD-3213 for the treatment of BPH is 8 mg once daily. The medication should be taken orally with or without food. Patients should be monitored for any signs of side effects, and the dosage may be adjusted based on their individual response to the medication.
Conclusion:
In conclusion, Silodosin KMD-3213 is an effective medication for the treatment of the symptoms of benign prostatic hyperplasia (BPH) that works by blocking the activity of alpha-1 adrenergic receptors in the prostate gland. It helps to improve urine flow and reduce the symptoms of BPH, such as urinary frequency, urgency, and difficulty urinating. Although Silodosin KMD-3213 has shown potential benefits in clinical trials, more studies are needed to establish its long-term safety and efficacy. Therefore, patients should always consult with their healthcare provider before starting any new medication
